This year’s biggest oncology conference delivered some surprisesand gave investors plenty to look forward to in the months ahead. Loxo Oncology Inc. (NASDAQ:LOXO), andTG Therapeutics(NASDAQ:TGTX) are already having a great year that could get a lot better, while recently beaten downNektar Therapeutics(NASDAQ:NKTR) will get a chance to redeem itself.
Here’s how the rest of the year could shake out for these cancer-driven biotech stocks.
Image source: Getty Images.
Loxo Oncology: First approval on the way?
This company’s personalized approach to cancer treatment wowed the crowd at the annual meeting of the American Society of Clinical Oncology for two straight years. While investors wait for more data from Loxo’s latest head-turner, the company could receive a speedy approval decision for last year’s belle of the ball, larotrectinib. The FDA is expected to deliver a decision on or before November 26 that could give this high-flying cancer stock more lift.
Top 5 Stocks To Own Right Now: Neptune Technologies & Bioresources Inc(NEPT)
- [By Maxx Chatsko]
Shares of Neptune Technologies & Bioressources (NASDAQ:NEPT) gained nearly 24% today after the company announced a new multiyear agreement with Canopy Growth (NYSE:CGC). The tiny technology company will supply cannabis extract products to complement the industry leader’s existing capabilities. Further information wasn’t disclosed.
- [By Max Byerly]
Here are some of the media stories that may have impacted Accern’s rankings:
Get Neptune Technologies & Bioressources alerts:
Neptune Technologies & Bioressources Inc. (NEPT) stock RSI touches to 33.20, it is oversold (nasdaqchronicle.com) Current Stocks are blowing up: BioLineRx Ltd. (NASDAQ:BLRX), Neptune Technologies & Bioressources Inc … (journalfinance.net) Damn Good Stocks: Neptune Technologies & Bioressources Inc. (NASDAQ:NEPT), Retractable Technologies, Inc … (thestreetpoint.com) Some business risks from marijuana regulation changes (canadianunderwriter.ca) Neptune Announces Fourth Quarter and Year-end Results (finance.yahoo.com)
Neptune Technologies & Bioressources traded down $0.05, hitting $2.45, during midday trading on Tuesday, according to Marketbeat. 12,695 shares of the company traded hands, compared to its average volume of 262,092. Neptune Technologies & Bioressources has a 52 week low of $0.70 and a 52 week high of $3.59.
- [By William Romov]
…or take a chance at 207% returns in just 49 days with penny stocks like Neptune Technologies & Bioressources Inc. (Nasdaq: NEPT)…
…these online discount brokers will allow you to do both.
Top 5 Stocks To Own Right Now: Intuit Inc.(INTU)
- [By Ethan Ryder]
Intuit (NASDAQ:INTU) VP Mark J. Flournoy sold 5,513 shares of the company’s stock in a transaction dated Thursday, May 24th. The shares were sold at an average price of $197.16, for a total transaction of $1,086,943.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
- [By Wayne Duggan]
With bitcoin prices now at their highest levels since March at above $9,200, former Intuit Inc. (NASDAQ: INTU) and Paypal Holdings Inc (NASDAQ: PYPL) CEO Bill Harris wrote an op-ed piece for Recode in which he called bitcoin “the greatest scam in history.” Harris said cryptocurrencies are massive pump-and-dump schemes and fraud artists are taking advantage of cryptocurrency investors naivety and greed. He added that bitcoin has no intrinsic value, isn't an effective store of value and isn't accepted by the vast majority of businesses, making it virtually useless as a means of payment.
- [By Stephan Byrd]
Intuit (NASDAQ:INTU) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $213.00 price target on the stock. According to Zacks, “We are optimistic on Intuit’s growing SMB exposure and believe that its strategic acquisitions will fortify this segment. Due to the continuously emerging new technologies and current market trends, cloud-based business and financial software solutions have been gaining momentum. As Intuit is already a market leader in this segment, the increased adoption helped it gain new customers, in turn, boosting the overall performance. Estimates have been stable for Intuit of late. Moreover, the company’s strategy of shifting its business to cloud-based subscription model will help generate more stable revenues over the long run. Intuit’s shares have outperformed the industry in a year’s time.”
- [By Daniel Sparks]
Intuit Inc.’s (NASDAQ:INTU) third-quarter earnings release showed a company firing on all cylinders. The financial software company saw a 15% increase in revenue, 12% higher operating income, and 45% growth in Quickbooks Online subscribers on a year-over-year basis. Topping it all off, Intuit raised its guidance for fiscal 2018 full-year revenue, to a 12% to 14% year-over-year increase in the key metric.
Top 5 Stocks To Own Right Now: Kingtone Wirelessinfo Solution Holding Ltd(KONE)
- [By Money Morning News Team]
While a 209% gain is exciting, FunctionX’s gains are in the past. After looking at the 10 top penny stocks to watch this week, we’ll show you a small-cap stock with serious profit potential ahead of it…
Penny Stock Current Share Price Law Week’s Gain
FunctionX Inc. (OTCMKTS: FNCX) $0.03 209%
Turtle Beach Corp. (Nasdaq: HEAR) $4.48 52.73%
DPW Holdings Inc. (NYSE: DPW) $1.16 51.31%
Energy XXI Gulf Coast Inc. (Nasdaq: EGC) $5.62 49.33%
MYnd Analytics Inc. (Nasdaq: MYND) $1.91 49.21%
Kingtone Wirelessinfo Solutions Holding Ltd. (Nasdaq: KONE) $6.43 48.42%
Rennova Health Inc. (OTCMKTS: RNVA) $0.02 44.30%
International Tower Hill Mines Ltd. (NYSE: THM) $0.72 41.64%
Blonder Tongue Labs Inc. (NYSE: BDR) $1.13 41.14%
Bellicum Pharmaceuticals Inc. (Nasdaq: BLCM) $8.87 40.53%
As the gains above suggest, penny stocks can provides tremendous returns for investors very quickly. However, it’s important to note that investing in penny stocks is also inherently risky.
Top 5 Stocks To Own Right Now: Vanda Pharmaceuticals Inc.(VNDA)
- [By Stephan Byrd]
Media stories about Vanda Pharmaceuticals (NASDAQ:VNDA) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vanda Pharmaceuticals earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.3857713397213 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
- [By Stephan Byrd]
Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Stephan Byrd]
Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have been assigned an average recommendation of “Buy” from the eight ratings firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $22.40.
Top 5 Stocks To Own Right Now: Tiptree Financial Inc.(TIPT)
- [By Joseph Griffin]
TRADEMARK VIOLATION WARNING: “Tiptree (TIPT) Raised to C at TheStreet” was posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3350618/tiptree-tipt-raised-to-c-at-thestreet.html.
- [By Tim Melvin]
This week, I ran across Tiptree Inc. (Nasdaq: TIPT) on the list of stocks with the highest VQScores. Tiptree fits most of my parameters as well so I spent a little time digging into the company further.